Quadrature Capital Ltd Raises Stake in Avanos Medical, Inc. (NYSE:AVNS)

Quadrature Capital Ltd grew its stake in shares of Avanos Medical, Inc. (NYSE:AVNS) by 67.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,207 shares of the company’s stock after purchasing an additional 9,320 shares during the quarter. Quadrature Capital Ltd owned approximately 0.05% of Avanos Medical worth $521,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Gladius Capital Management LP bought a new position in Avanos Medical in the third quarter worth about $30,000. Fulton Bank N.A. acquired a new position in shares of Avanos Medical during the fourth quarter valued at about $228,000. Natixis Advisors L.P. acquired a new position in shares of Avanos Medical during the fourth quarter valued at about $317,000. Quest Partners LLC acquired a new position in shares of Avanos Medical during the fourth quarter valued at about $327,000. Finally, Dark Forest Capital Management LP purchased a new stake in Avanos Medical in the third quarter valued at approximately $372,000. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Trading Up 0.6 %

Avanos Medical stock opened at $19.56 on Monday. The company has a current ratio of 2.28, a quick ratio of 1.47 and a debt-to-equity ratio of 0.14. Avanos Medical, Inc. has a 12 month low of $17.24 and a 12 month high of $26.56. The stock’s 50 day simple moving average is $19.49 and its two-hundred day simple moving average is $19.75. The firm has a market cap of $897.80 million, a PE ratio of -14.71 and a beta of 0.98.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.02). Avanos Medical had a positive return on equity of 4.10% and a negative net margin of 9.15%. The company had revenue of $166.10 million during the quarter, compared to analysts’ expectations of $162.90 million. During the same quarter in the prior year, the company posted $0.27 EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Analysts anticipate that Avanos Medical, Inc. will post 1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. JMP Securities reiterated a “market perform” rating on shares of Avanos Medical in a research report on Tuesday, May 7th. StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 11th.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.